Vornorexant Tablets (Vornorexant) are a new type of medication for treating insomnia, classified as an orexin receptor antagonist. It helps patients transition naturally into sleep by inhibiting the action of "orexin"—a neuropeptide in the brain that promotes wakefulness.

Side Effects of Vornorexant Tablets

Nervous System-Related Side Effects

The most common adverse reaction is somnolence (drowsiness), with an incidence of approximately 3% to 11.5% in clinical trials. The incidence increases with higher doses (e.g., 10 mg) or long-term use.

A small number of patients may experience floating dizziness or sleep paralysis (a state where consciousness is clear but the body is temporarily unable to move).

Psychiatric and Systemic Reactions

Some patients have reported nightmares, with an incidence ranging from 1% to 3%.

A small number of other patients may experience fatigue, or elevated lactate dehydrogenase levels in the blood detected during examinations. The elevation is generally mild, but regular monitoring is still required during medication use.

Severe Side Effects of Vornorexant Tablets

Central Nervous System Depression and Impact on Daytime Function

This medication may cause next-day drowsiness, poor concentration, and decreased reflex motor ability, which can affect activities requiring high alertness, such as driving or operating machinery.

Engagement in hazardous work should be absolutely avoided during the medication period.

Dependence Risk

Vornorexant Tablets are classified as "habit-forming pharmaceuticals," meaning they have the potential for addiction or dependence.

Long-term use may lead to psychological or physical dependence. Therefore, do not increase the dose on your own or abuse the medication long-term; it should be used as needed and for short periods under the guidance of a doctor.

Severe Risks in Special Populations

Patients with hepatic impairment: Use is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). Impaired drug metabolism will lead to a significant increase in blood drug concentration, exacerbating side effects.

Patients with respiratory dysfunction: Except for mild obstructive sleep apnea, the safety of this medication in patients with other respiratory insufficiencies has not been established, and careful evaluation is required.

Patients with psychiatric or neurological diseases: For example, patients with narcolepsy or cataplexy may experience worsening symptoms after medication use; patients with organic brain lesions may be more sensitive to the drug’s effects.

Important Precautions for Vornorexant Tablets

Medication Warnings for Special Populations

Pregnant women: Use only when the therapeutic benefit outweighs the potential risk.

Lactating women: The necessity of treatment and the benefits of breastfeeding should be comprehensively considered to decide whether to discontinue the medication or stop breastfeeding.

Children: Safety has not been established, and use is not recommended.

Behavioral and Lifestyle Guidance

Alcohol consumption is prohibited during the medication period, as alcohol enhances the central inhibitory effect of the drug.

Avoid drinking grapefruit juice, as it inhibits drug metabolism and increases blood drug concentration.

If symptoms improve, do not rely on the medication long-term. The decision to continue treatment should be made after evaluation by a doctor.